Literature DB >> 14599962

Analysis of gene expression profiles in pancreatic carcinoma by using cDNA microarray.

Xian-Jun Yu1, Jiang Long, De-Liang Fu, Qun-Hua Zhang, Quan-Xin Ni.   

Abstract

OBJECTIVES: To survey the gene expression profiles in pancreatic carcinoma by using cDNA microarray and detect target genes for further study.
METHODS: Three mixed samples from 2 cases of normal pancreatic tissue and 4 cases of moderate-differentiated pancreatic carcinoma were studied by means of cDNA microarray consisting of 18 000 genes.
RESULTS: 1484 and 1353 different expressed genes were observed in two cancer samples respectively. We identified 455 genes altered with the same tendency in both samples, including 102 up-regulated and 353 down-regulated genes. There were 274 known genes and 181 unknown genes; 27.8% and 52.0% genes respectively had an expression level in cancer that was 2-fold higher or lower than that in normal samples. Tumor suppressor genes, growth factors and receptor genes, signal conduction genes, transcription factor genes were identified.
CONCLUSIONS: cDNA microarray is an efficient and high-throughout method to investigate gene expression profiles in pancreatic carcinoma. MBD1, EDG1 and gene hypermethylation mechanism would play an important role in the pathogenesis of pancreatic carcinoma.

Entities:  

Mesh:

Year:  2003        PMID: 14599962

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  7 in total

1.  Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer.

Authors:  Sally E Dowen; Tatjana Crnogorac-Jurcevic; Rathi Gangeswaran; Mikkel Hansen; Jyrki J Eloranta; Vipul Bhakta; Teresa A Brentnall; Jutta Lüttges; Gunther Klöppel; Nick R Lemoine
Journal:  Am J Pathol       Date:  2005-01       Impact factor: 4.307

2.  Effect of antisense MBD1 gene eukaryotic expression plasmid on expression of MBD1 gene in human biliary tract carcinoma cells.

Authors:  Shi Zuo; Shengquan Zou; Jian Luo; Wei Guo; Lining Xu; Jingqing Dong; Minfeng Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

Review 3.  Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.

Authors:  Sau Wai Hung; Hardik R Mody; Rajgopal Govindarajan
Journal:  Cancer Lett       Date:  2012-03-13       Impact factor: 8.679

Review 4.  Interdiction of sphingolipid metabolism to improve standard cancer therapies.

Authors:  Thomas H Beckham; Joseph C Cheng; S Tucker Marrison; James S Norris; Xiang Liu
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

5.  Identifying Biomarkers and Drug Targets Using Systems Biology Approaches for Pancreatic Cancer.

Authors:  Yi Tan; Lucio Miele; Fazlul H Sarkar; Zhiwei Wang
Journal:  Pancreat Disord Ther       Date:  2012-12-06

6.  LCL124, a cationic analog of ceramide, selectively induces pancreatic cancer cell death by accumulating in mitochondria.

Authors:  Thomas H Beckham; Ping Lu; Elizabeth E Jones; Tucker Marrison; Clayton S Lewis; Joseph C Cheng; Venkat K Ramshesh; Gyda Beeson; Craig C Beeson; Richard R Drake; Alicja Bielawska; Jacek Bielawski; Zdzislaw M Szulc; Besim Ogretmen; James S Norris; Xiang Liu
Journal:  J Pharmacol Exp Ther       Date:  2012-10-18       Impact factor: 4.030

7.  Proteomic analysis of differential proteins in pancreatic carcinomas: Effects of MBD1 knock-down by stable RNA interference.

Authors:  Chen Liu; Yaohui Chen; Xianjun Yu; Chen Jin; Jin Xu; Jiang Long; Quanxing Ni; Deliang Fu; Hong Jin; Chen Bai
Journal:  BMC Cancer       Date:  2008-04-29       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.